201 related articles for article (PubMed ID: 10756056)
1. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Ziermann R; Limoli K; Das K; Arnold E; Petropoulos CJ; Parkin NT
J Virol; 2000 May; 74(9):4414-9. PubMed ID: 10756056
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
[TBL] [Abstract][Full Text] [Related]
4. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
Race E; Dam E; Obry V; Paulous S; Clavel F
AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
[TBL] [Abstract][Full Text] [Related]
5. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors.
Maguire M; Shortino D; Klein A; Harris W; Manohitharajah V; Tisdale M; Elston R; Yeo J; Randall S; Xu F; Parker H; May J; Snowden W
Antimicrob Agents Chemother; 2002 Mar; 46(3):731-8. PubMed ID: 11850255
[TBL] [Abstract][Full Text] [Related]
6. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
7. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
Schmidt B; Korn K; Moschik B; Paatz C; Uberla K; Walter H
Antimicrob Agents Chemother; 2000 Nov; 44(11):3213-6. PubMed ID: 11036057
[TBL] [Abstract][Full Text] [Related]
8. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Martinez-Picado J; Wrin T; Frost SD; Clotet B; Ruiz L; Brown AJ; Petropoulos CJ; Parkin NT
J Virol; 2005 May; 79(10):5907-13. PubMed ID: 15857976
[TBL] [Abstract][Full Text] [Related]
10. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
Gallego O; Corral A; de Mendoza C; Soriano V
Clin Infect Dis; 2002 May; 34(9):1288-9. PubMed ID: 11941567
[No Abstract] [Full Text] [Related]
13. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
Lam E; Parkin NT
Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
[No Abstract] [Full Text] [Related]
14. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
15. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
[TBL] [Abstract][Full Text] [Related]
16. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
Rocheblave L; Bihel F; De Michelis C; Priem G; Courcambeck J; Bonnet B; Chermann JC; Kraus JL
J Med Chem; 2002 Jul; 45(15):3321-4. PubMed ID: 12109915
[TBL] [Abstract][Full Text] [Related]
18. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
20. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
